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Infections and responses to infections are one proposed cause of preeclampsia. 
Infections can originate from distant sites e.g., mouth. Pattern recognition receptors 
(PRRs) are a group of molecules that identify essential parts of microbes, e.g., 
peptidoglycan, and help respond to infections. Peptidoglycan can trigger responses at 
the placenta, resulting in secreted proteins, from placenta into the blood, leading to pre-
eclampsia. Peptidoglycan recognition proteins (PGRP) are newly discovered group of 
PRRs that kill bacteria and can digest peptidoglycan, thereby potentially influencing 
disease processes like preeclampsia. Through this study we propose to investigate the 
role of PGRP in preeclampsia. Infections and subsequent host responses activated 
through pattern recognition receptors (PRRs), e.g., TLR-2 & TLR-4, can cause 
preeclampsia. PRRs recognize essential bacterial patterns, like cell-wall components, 
e.g., peptidoglycan & lipopolysaccharide, and trigger trophoblast apoptosis and robust 
pro-inflammatory responses at the maternal-fetal interface. Microbes/microbial patterns 
can originate from distant sites e.g., infected gingiva, and activate placental responses. 
Peptidoglycan recognition proteins are a newly discovered group of PRRs that are 
bactericidal and are thought to modulate inflammatory responses. The role of PGRPs in 
the pathogenesis of preeclampsia will be elucidated through this project. 
Preeclampsia (PE) is a pregnancy related disease and is one of the complications 
of human pregnancy [1]. It occurs in at least 3-14% of all pregnancies with a risk of 
recurrence between 7.5 to 65% [2]. It originates in the placenta and remains a leading 
cause of maternal and fetal morbidity and mortality [2]. There are over 76,000 maternal 
and 500,000 fetal deaths, annually due to PE [2]. PE is commonly understood as a 
hypertensive disorder of pregnancy, characterized by increased blood pressure 
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accompanied by proteinuria, both occurring after 20 weeks gestation and may also cause 
intrauterine growth restriction of the fetus [2]. PE also poses a threat of increased risk for 
development of future cardiovascular disease [3]. The causes for the development of PE 
are largely unknown and reflects the limited understanding of the immunobiology and 
inflammatory pathways in normal and abnormal pregnancies[1]. Despite decades of 
intense research, there is no early pregnancy-screening test to recognize those at risk for 
PE [2]. Symptomatic treatment is the only option for this condition and the only known 
cure is delivery [4]. 
Different hypotheses have been proposed for the pathogenesis of PE. Failure of 
physiological transformation of myometrial spiral arteries leads to inadequate 
placentation which results in PE [5]. The exact mechanisms that cause inadequate 
trophoblast invasion and consequent abnormal placentation are not known. Recently, 
altered immune-inflammatory responses at the placental level have been suggested to be 
involved in pathogenesis of PE. Interestingly, PE is characterized by intravascular 
inflammation and endothelial cell dysfunction [6, 7]. These immune-inflammatory 
responses at the placental level are thought to be in response to infectious agents.  
Chronic infections at distant sites could be a potential sources for such infectious 
agents, e.g., infectious diseases of the oral cavity like chronic periodontitis and various 
types of infections like periapical abscesses, granuloma etc. [11]. Oral infections, 
particularly periodontal diseases are near ubiquitous and affect 70%-90% of the adult US 
population. The frequent bacteremic episodes, detection of circulatory bacterial cell wall 
components, and the potential spillover effects of local inflammatory mediators 
originating from diseased gingiva are thought to contribute to an increase in systemic 
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inflammation [33].  Oral pathogens e.g., Porphyromonas gingivalis, Fusobacterium 
nucleatum etc., and their components have been detected in chorioamnionitis. Favorable 
conditions may permit the survival of selective bacterial species from oral cavity to enable 
it to travel through the circulation and become enriched at the placental bed [8]. In fact 
periopathogenic bacteria have been identified in greater frequency in the placenta of 
women with PE as compared to control subjects [9]. Oral bacterial antigens like 
peptidoglycan (PGN) and their fragments by themselves can reach the placental bed [10]. 
Additional clinical associative links point to a connection between oral infections and PE. 
For example, several studies have suggested that periodontal disease may be associated 
with increased risk for PE [11]. Periodontitis is a chronic immuno-inflammatory disease 
initiated and propagated by host response to dental biofilm and is one of the most 
prevalent chronic diseases in humans[12].  Periodontal disease is reported to affect 20-
50% of pregnant women especially of lower socio-economic status[11] Maternal 
periodontal disease is shown to be associated with increased risk for development of PE, 
independent of the effects of maternal age, race, smoking, gestational age at delivery, and 
insurance status[13]. Additionally, since the pathogenesis of periodontal disease occurs 
through an infective-inflammatory axis, it has been proposed to potentially cause an 
increase in the levels of endotoxins, bacterial components, inflammatory cytokines and 
oxidative stressors in the systemic circulation. This increase may have consequences at 
the maternal fetal interface i.e., placenta in pregnant women. Therefore it has been 
proposed that periodontitis may be a vascular stressor that plays a role in the development 
of PE[11] . 
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The infectious-inflammatory axis is initiated by innate recognition of microbes. 
Innate microbial recognition occurs through evolutionarily conserved host receptors 
called pattern recognition receptors [14]. Examples of PRRs include a group of proteins 
called toll like receptors (TLR) [14] and nuclear oligomerization domain (NOD) like 
receptor proteins[15],[16].These PRRs recognize molecular patterns of components that 
are essential for survival of the microbes. These patterns are collectively called microbial 
associated molecular patterns (MAMPs). Each of the MAMPs have specific cognate 
PRRs; for example, TLR-4 recognizes a gram negative bacterial cell wall component i.e., 
lipopolysaccharides [14] while TLR-2, NOD-1 and NOD-2  are thought to sense another 
cell wall component of both gram positive and gram negative bacteria, i.e., 
peptidoglycans[15],[16]. NOD receptors are primarily intra-cellular receptors and 
therefore recognize peptidoglycans of phagocytized microbes or its components. Among 
the MAMPs PGN is particularly interesting because the polymeric PGN and each of its 
enzymatically digested fragments have different sets of cognate PRRs producing diversity 
in how the host responds to PGN. Gram-negative and Gram-positive bacteria have PGN 
as integral part of their cell wall but have significant differences in their structural make 
up that the host cells can differentiate.  
PGN can be released into the systemic circulation in a number of ways: a) during 
PGN turnover as part of bacterial division, b) through host or other microbial hydrolases 
or c) bacterial lysis. PGN thus released has been found in distant sites, e.g., from gut to 
systemic circulation and found in brain. As mentioned earlier PGN and its breakdown 
products have different cognate PRRs. Polymeric PGN is recognized extracellularly by 
TLR-2, and CD14. Intracellularly fragments of PGN namely, mesoDAP-containing 
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tripeptides (TriDAP) found predominantly in Gram- Negative bacteria, and muramyl 
dipeptides (MDP) found in both Gram-negative and Gram positive species are recognized 
by NOD1 and NOD2 respectively. PGN and its fragments have been proposed to instruct 
the development of host immune response especially PGN fragments released from the 
gut into systemic circulation.  It is conceivable that such a similar instruction takes place 
at the maternal – fetal interface to establish homeostasis during pregnancy. Disruption of 
this instruction can potentially lead to disorders like preeclampsia. 
A new class of PRRs called peptidoglycan recognition proteins (PGRP) 
constituting four distinct molecules PGRP-1, PGRP2, PGRP3 and PGRP4, each with 
distinct functions, are emerging as key player in modulating host responses to PGN and 
its breakdown products [17].   Binding of PGRPs to peptidoglycans and bacteria suggests 
their direct role in recognition of bacteria. However, the consequences of this binding and, 
thus, the exact role of PGRPs in innate immunity to bacteria in mammals, are largely 
unknown[18]. Constitutive PGRP expression has been demonstrated in various tissues 
including oral mucosal tissues and the tongue [17]. PGRPs are mostly stored in vesicles 
and/or secreted. Therefore, they are likely to act in different cellular or tissue 
compartments as compared to NODs [19]. Mammalian PGRP-1 is expressed in high 
levels in the bone marrow, specifically in neutrophils and their precursors. In neutrophils, 
PGRP-1 is almost exclusively found in tertiary granules from where it can be released by 
exocytosis. It is also expressed in low quantities in oral epithelial cells and fibroblasts and 
can be inducibly up-regulated in these cells in response to peptidoglycans[17]. PGRP-2 is 
constitutively expressed in liver, which secretes it into blood. It is also expressed in lower 
levels in oral epithelial cells. Its expression is up-regulated in these cells and fibroblasts 
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by bacteria and cytokines in a NOD-2 dependent manner [17]. PGRP-2 is also known to 
enzymatically cleave peptidoglycan. PGRP-3 and PGRP-4 are found in salivary glands, 
specifically submandibular glands and in other oral tissues including tongue and throat.  
Their expression is also up regulated by bacteria in keratinocytes, fibroblast and other 
cells through TLR-2, TLR-4, NOD-1 and NOD-2 [17].  
PGRP1, 3 & 4 are bactericidal and act by activating the two component bacterial 
lethal stress response signal transduction systems. PGRP-2 is an amidase that can 
hydrolyze PGN and some of its breakdown products [20]. In addition, PGRPs have been 
shown to modulate the microbiome as well as the inflammatory response. PGRP1 has 
pro-inflammatory effects; while PGRP3 & PGRP4 are thought to suppress inflammatory 
cytokine expression in response to TLR/NOD signaling [21]. For example, knock out of 
PGRP-1 protects mice from experimental asthma. Knock out of PGRP-2, 3 and 4 results 
in inflammatory diseases like arthritis, psoriasis etc. in mice [17]. These experimental 
findings also suggest a modulatory effect on inflammation by various PGRPs independent 
of their bactericidal/enzymatic effects [22].  
This evidence further suggests a role for PGRPs in the pathogenesis of various 
microbial triggered inflammatory diseases like psoriasis, atherosclerosis, arthritis, 
ulcerative colitis, and Crohn’s disease [17]. PGRP-1 is shown to be associated with 
hypertension in a population based multidisciplinary cardiovascular study [23]. PGRP-2 
is particularly intriguing as it breakdowns PGN and depending on the context may serve 
to reduce pro-inflammatory effect of PGN, shift the response from anti-inflammatory 
NOD2 signaling to NOD1 signaling in addition to enhancing bacterial killing by 
antibacterial peptides.  
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Not much is known about the role of PGRP at the maternal –fetal interface, 
particularly during pathogenesis of PE. Innate immune responses, specifically TLR and 
NOD mediated responses at the level of trophoblasts, specialized fetal epithelial cells of 
the placenta, and placenta have been implicated in the pathogenesis of PE. For example, 
TLR-4 protein expression is increased in trophoblasts in the placental samples of patients 
with pre-eclampsia [24]. Proinflammatory cytokines that are released from macrophages, 
dendritic cells, and T cells through activation of TLRs can result in inhibition of 
trophoblast migration. These cytokines can also be directly cytotoxic to trophoblasts. It 
has been demonstrated that TLR-4 expression results in inhibition of trophoblast 
migration and TLR-2 expression causes apoptosis of trophoblasts[24]. Activation of NOD 
has also been implicated in inflammatory reactions at the fetal-maternal interface. 
Interestingly PGRPs are expressed downstream of TLR-2 and NOD like proteins 
[21]. Human oral epithelial cells exhibit enhanced PGRP expression in response to 
synthetic ligands targeting TLRs and NODs in both cases through activation of nuclear 
factor-κB. This activation interestingly did not result in increased inflammatory cytokine 
expression. This suggests a possible immune modulatory effect of PGRPs on TLR and 
NOD signaling.  
Dysregulation of this immune modulation, especially in the placenta may result in 
adverse pregnancy outcomes like PE. Proteomics based studies provide tantalizing hints 
on the importance of PGRP in the context of pregnancy. Cervical mucous plugs show 
elevated levels of PGRPs. Granulocyte associated PGRP was found to be increased in 
conceptus fluid of bovine miscarriages, which were a result of infections. The authors of 
that study speculated that increased levels of PGRPs is probably a direct response to an 
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immuno-inflammatory episode caused by either microbial invasion of the uterine/ 
conceptus space or as a consequence of an inflammatory event [25].  
The immune-inflammatory responses to microbes are mediated by recognition of 
bacterial components called microbial associated molecular patterns (MAMPs) through 
conserved cognate receptors called pattern recognition receptors (PRRs). One such 
critical MAMP, bacterial cell wall component peptidoglycan (PGN) and cognate 
receptors are off particular interest in the context of homeostasis at the maternal-fetal 
interface. A new class of PRRs called peptidoglycan recognition proteins (PGRP) 
constituting four distinct molecules PGRP 1-4 is emerging as key player in modulating 
host responses to PGN and its breakdown products.  
Not much is known about the expression and function of these proteins in the maternal-
fetal interface. Proteomics based studies provide tantalizing hints of their importance in 
the context of pregnancy. It is well known that PGN can contribute to preeclampsia by 
either apoptosis of trophoblasts and subsequent release of damage associated molecular 
patterns (DAMPs) in to the circulation or through increase of proinflammatory 
cytokines into the systemic circulation. Considering that, PGRP can modulate PGN 
response; the precise role or PGRP at the maternal fetal interface needs further 
exploration.  
Taken together, we propose that a critical knowledge gap exists on the role of PGRPs 
in the innate immune responses that occur at the maternal-fetal interface in response to 
pathogens and their components that may be present in maternal circulation secondary 
to chronic infections like gingivitis and periodontitis. It is conceivable that PGRPs may 
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be differentially regulated in healthy pregnancies and during preeclampsia. Therefore, 
the aim of this project is: 
 
To evaluate the expression of PGRPs in pre-eclamptic human placental tissue in 
comparison with patients without pre-eclampsia 
 
The overall goal of this project was to establish the role of PGRPs in the pathogenesis 
of preeclampsia. An additional goal was explore the potential link between oral 
pathogens and innate immune responses at the maternal-fetal interface. Considering 
that PGRPs are secreted proteins and therefore are quantifiable, the results of this study 
could lead to development of salivary and/or plasmatic biomarkers for early detection 
of pre-eclampsia. Understanding the role of PGRPs at the maternal-fetal interface may 
also provide potential new therapeutic targets for treating pre-eclampsia. 
Preliminary Data: 
Since no data was available on the expression of PGRP in the human placenta, we 
decided to investigate the mRNA expression of various PRRs in pooled placental sample 
from different subjects and compared it with three different unstimulated trophoblast cell 
lines, namely SW71, 3a-Sub-E and HTR8. We noted that PGRP1 and PGRP3 were 
expressed constitutively in all the cell lines. The pooled placental sample had elevated 
mRNA expression of PGRP1 (30 fold) and PGRP3 (400 fold) when compared with cell 
lines (Figure 1). Similarly, TLR2, TLR4 and NOD2 mRNA were elevated in placental 
samples. (Figure 1, unpublished data) We also noted differences in expression for the 
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various PRRs between the trophoblast cell lines (Figure 1 unpublished data). 
Surprisingly, we didn’t detect any PGRP4 in either the cells lines or in the pooled 
placental sample.  As expected, PGRP2 was not expressed in placenta, consistent with its 
role as a circulatory scavenger expressed by liver into the systemic circulation. 
 
 
 
 
 
 
 
 
 
 
 
The role of TLR and NOD mediated immune responses in the pathogenesis of 
periodontitis has been extensively documented. As discussed previously, periodontal 
pathogens have also been implicated in adverse pregnancy outcomes. The presence of 
periodontal pathogens and their components in the maternal circulation, secondary to 
chronic infection in the oral cavity, can result in activation of immune response at the 
maternal fetal interface, which may involve PGRPs. We have noted significant increase in 
Figure 1: Relative mRNA expression of various PRRs in 
Placenta and in trophoblasts normalized to beta actin mRNA.  
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PGRP 1, 2 and 3 in gingival tissue of subjects with chronic periodontitis when compared 
to health (Figure 2 unpublished data). The robust elevation of PGRP2 in periodontal 
tissues might be secondary to elevated levels in systemic circulation in response to oral 
infection or alternatively PGRP2 maybe elevated locally in periodontal tissue. Therefore, 
oral infections may elevate PGRP2 in systemic circulation, having consequences for 
distant sites when there is presence of coexisting infectious agents in the circulation. 
 
 
         
 
 
 
 
 
 
 
We also included immunohistochemically quantifying expression of different 
PGRPs in gingival tissues and categorizing their inflammatory status by histological 
analysis and correlating it back to the mRNA levels. 
  The overall goal of the research project was to understand the role of innate 
immunity in the pathogenesis of PE and in addition to explore the contribution of 
Figure 2: Relative mRNA expression of PGLYRPs in health 
and disease.  
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periodontal diseases in the pathogenesis of PE. Specifically, the current study will 
investigate the expression of a group of innate immune pattern recognition receptors 
(PRRs), called Peptidoglycan Recognition Proteins (PGRP), in the placenta of pre-
eclamptic women.  
 
Hypothesis: PGRPs are expressed in the human placenta and differ in their expression in 
pre-eclampsia compared with normal controls. 
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Materials and Methods 
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Study design & Sample size determination 
A case control study was conducted to examine the expression pattern of PGRP-1, 
2, 3, & 4 in placental biopsy specimens through real time RT-PCR. Originally, the study 
design was adapted from Kim et al 2005[24]. The sample size for the proposed study was 
estimated based on differences in levels of TLR-4 as published in the study by Kim et 
al[24]. Their study, with 15 placental samples per test group, and 20 samples in control 
group noted differences in TLR expression between health and disease in human placental 
samples, with effect sizes ranging from 3.4 (significant) to 0.4 (non-significant) 
depending on the TLR. With a sample size of 20 subjects in the test group (pre-eclamptic 
samples) and 20 in control group (normal samples), the proposed study was designed to 
have 80% power to detect an effect size of 1.0, assuming two-sided tests each conducted 
at a 5% significance level.  
Experimental Groups: 
The pilot study groups consisted of subjects with: (1) uncomplicated term 
pregnancies (n=7) (2) pre-eclamptic group  (n=7). Pregnancies were considered normal 
when there was no evidence of medical and/or obstetric complications and the birth 
weight appropriate for gestational age (term, ≥ 37 weeks of gestation). Preeclampsia was 
defined as hypertension (systolic blood pressure of ≥ 140 mm Hg or diastolic blood 
pressure of ≥ 90 mm Hg on at least 2 occasions, 4 hours to 1 week apart) and proteinuria 
(≥ 300 mg in a 24-hour urine collection or one dipstick measurement of ≥ 2+). Only 
patients who delivered via Cesarean- section were included. Patients with diabetes, 
chorioamnionitis (bacterial infection of the amniotic fluid and the membranes surrounding 
the fetus) and multiples (twins, triplets) were excluded from the study. The cases and 
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controls were matched according to the maternal age, gestational age, BMI, race and 
ethnicity. The placental samples were obtained from an existing collection of tissues in 
Dr. Jill Reiter’s lab and the IUPUI Building Blocks Pregnancy Biobank. Study approval 
was obtained from the Institutional Review Board of Indiana University Purdue 
University, Indianapolis.  
This project was done in collaboration with the Department of Obstetrics and 
Gynecology at the Indiana University School of Medicine. The project was carefully 
discussed and reviewed from its inception with research as well as clinical faculty from 
the Dept. of OB/GYN. The collaborators of the project include Dr. Jill Reiter (Director, 
Perinatal Epigenetics Research Laboratory, Assistant Professor of Obstetrics and 
Gynecology, Maternal Fetal Medicine Division) and Dr. David Haas (Associate Professor 
of OB/GYN, Vice Chair for Research, Dept. of OB/GYN). 
Sample Collection:  
 All the samples used for the study purposes were de-identified and assigned a 
study number which could be linked back to their hospital records by authorized 
personnel only if need be, for any additional information regarding their health history.  
Some of the placental samples were available in Dr. Reiter’s lab. Dr. Reiter had 
been collecting placental samples for research purposes for the last three to four years. 
Information of a potential delivery would be sent to the research personnel at the lab who 
would to go the IU Hospital delivery room to secure the placenta in a timely manner. 
Typically 4-5 core samples of the placenta would be taken with a specialized metal biopsy 
tool as shown in the picture below (Figure 3). The secured samples would then be stored 
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in - 80°C freezer for RNA extraction at a later time.  
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure 3: Securing placental samples 
 
 The inclusion and the exclusion criteria of the cases and controls were submitted 
to the coordinator of the IU Building Blocks Pregnancy Biobank. Once the list of possible 
samples were returned to us, selection of the appropriate samples from that list would be 
made. The placental samples were then delivered to Dr. Reiter’s lab from the storage 
facility on dry ice.  
Once the samples were delivered to the lab, they were weighed and about 100μg 
of the sample was secured for the study purposes and the rest of the specimen was 
returned to the Biobank.  
Human RNA isolation & cDNA conversion 
Total RNA was isolated from placental tissues using RNeasy Mini Kit (Qiagen 
Sciences, Valencia, CA) as per the manufacturer’s protocol and previously described [26]. 
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Tissue disruption and homogenization was carried out with a MagNA Lyser shaking-type 
bead mill (Roche) using 1.4 mm ceramic beads. RNA isolation was carried out according 
to the manufacturer’s instructions (Ambion TRIzol and PureLink RNA mini kit). DNase I 
treatment was performed on column before elution of the RNA. 
 
             
 
Figure 4: MagNA Lyser 
Source: UMass.edu 
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Figure 5: Ceramic Beads for tissue homogenization 
 
Tissue Homogenization 
Before     After 
 
 
Figure 6: Pre and Post tissue homogenization 
Source: Homogenizers.net 
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Total RNA extracted was quantified and integrity was determined by measuring 
the RNA quality index (RQI) using RNA StdSens chips on an Experion automated 
electrophoresis station (Bio-Rad Laboratories). Random hexamer primed reverse 
transcription will be performed using an cDNA synthesis kit (Qiagen Sciences, Valencia, 
CA) per manufacturer instruction. The reaction mixture was incubated under the 
following conditions: 5 min at 25oC, 30 min at 42oC, and 5 min at 85oC [26]. Genomic 
DNA elimination was done per manufacturer instructions.  Once the samples are loaded 
RQI- an algorithm which estimates the level of degradation in total RNA samples. 
 
 
Figure 7: This is a RNA Chip where the samples are loaded into  
each well, which gives an output that looks the image below 
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  Figure 8: Electropherogram 
 
                 
Figure 9: Virtual Gel Image 
RQI of 10 indicates intact RNA and 1 indicates degraded RNA 
RQI of 7-10 indicates acceptable quality RNA. 
1 
2 
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PCR array: 
A custom PCR array (Catalog # CAPH11996; Qiagen, Frederick, MD) was used 
to analyze relative mRNA expression of the following pattern recognition receptors 
TLR2, TLR4, NOD1, NOD2, PGLYRP1, PGLYRP2, PGLYRP3, and PGLYRP4. B-actin 
and GAPDH were used as house keeping genes. The Array had appropriate controls to 
evaluate for human genomic DNA contamination, reverse transcription control and a 
positive PCR control. The array was validated with periodontal tissue specimens. Below 
image illustrates the plate layout with a total of 96 wells with a single sample loaded 
across the row in each of the 12 wells.  
 
 
Figure 10: PCR plate layout 
Source: Qiagen.com 
Quantitative real-time polymerase chain reaction 
Per manufacturer instruction 500ng of cDNA for each placental sample was mixed 
with appropriate amounts of SYBR green (per manufacturer instruction) and loaded into 
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the PCR array wells. CDNA was amplified using SYBR Green super mix with an ABI 
Prism 700 real-time PCR machine (Applied Bio systems, Foster City, CA). Melting curve 
analysis was performed to confirm that the detected signal is that of SYBR Green binding 
to the expected amplification product and not to the possible primer-dimers. Duplicate 
reverse transcriptase reactions and a single PCR amplification were performed and 
expressed as relative amounts of housekeeping gene b-actin and GAPDH through the 
Pfaffl method [27].  
Immunohistochemistry (IHC): 
Antibodies made in rabbits immunized with the indicated KLH-conjugated 
peptides and purified by peptide-affinity chromatography, frozen in 50% glycerol were 
used for the IHC. The antibodies used were obtained from Dr. Roman Dziarski’s lab at 
IUSM, Gary, Indiana as well as commercially available antibodies (Novus, Cloud Clone 
Corp.) were used. All the antibodies were polyclonal, PGRP1 antibody was obtained from 
goat and the remaining (PGRP 2,3,4) were rabbit antibodies. The staining part of the IHC 
was done by the lab personnel at IU Pathology Lab. 
Statistical Analysis: 
Summary statistics (mean, standard deviation, range, 95% confidence interval for 
the mean) were calculated for PGLYRP 1-4 expression for each group. Two sample t- 
tests were used to test for group differences in PGLYRP 1-4 expression. Correlation 
coefficients were calculated between the expression levels of different receptors to 
examine possible association of expression. 
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Results: 
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A total of 14 samples were tested in a pilot study, 7 pre-eclamptic cases and 7 
controls. Upon examination of the partial data from this study to verify the assumptions 
used in the calculations, we determined that the study would need to detect an effect sizes 
of 0.3 to 0.5, which would require sample sizes of 64 to 176 per group. Having such a 
large sample size would be a good long-term study but for the purposes of this pilot 
resident project, a total of 14 samples were used. 
The cases and controls were matched as best as practically possible minimizing 
the risk for bias. The average age of the sample population was 27.6±8.7years. The mean 
age of the cases was 27.8 ± 5.1 years and the mean for the controls was 31.4 ± 3.9 years. 
The average BMI of the population was 31.3 ± 10.4, the average BMI for the cases was 
33.1 ± 5.1 and for the controls the average BMI was 34.2 ± 6.7. Out of the 7 cases, 6 were 
Caucasian, 1 was African American. For the control group, 5 samples were Caucasian, 1 
African American and 1 was unknown. 
 
 
Table 1: Demographics 
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RT- PCR Analysis: We wanted to confirm the expression of PGRPs in placenta before 
assessing their expression in the normal and diseased specimens. In order to do that, we 
perform PCR analysis with placental samples and positive controls known to express 
these protein molecules. The positive controls used were tissues from human brain, 
liver, skin, T-cells (Jurkat cell lines). The results from this analysis showed expression 
of PGRPs 1, 3 and 4 (purple curve) in the placental samples. However, the expression 
levels were low compared with the positive controls. Figure 11 is an amplification 
curve generated from the PCR data demonstrating the expression of PGRPs 1, 3 and 4.  
The PCR reaction theoretically doubles the DNA amount after completing each cycle, 
so it is an exponential reaction. The reaction, however, finally tails off and reaches a 
plateau, which is represented by the red arrow on the top of the image and is the end 
point of data collection at plateau (gel analysis). The center arrow is a representation of 
the reactions that start varying due to reagent depletion & decreased PCR efficiencies 
(enzyme activity, more product competing for primer annealing) and the bottom arrow 
demonstrates that the real time PCR does early phase detection at the exponential state. 
The x-axis is the cycle number where the curve crosses and the y-axis ∆Rn is the 
fluorescence signal with baseline subtracted (background signal subtracted). This step 
also enabled us to confirm that the assays were working, therefore reducing the 
potential for any false positives and/or negative results.  
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Figure 11: PGRP expression in placenta and positive controls (Amplification Plots) 
 
The PCR data showed the expression of PGRPs 1, 3 and 4 in the pre-eclamptic 
samples. PGRP1, PGRP3, and PGRP4 expression was not significantly different between 
the three groups (p value≥ 0.05). However, the clinical significance of this difference is 
yet to be determined. The fold changes in expression were calculated by the ΔCt method.  
Ct (Threshold cycle) is the cycle number at which the fluorescence signal crosses 
threshold. So a fold change of expression (up or down regulation) = Difference between 
the target gene and the reference gene. Here the target gene(s) is PGRP and the reference 
gene is NOD-1. A decrease in CT value increases expression. There was an up-regulation 
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of PGRP-1 (1.4 fold) and down regulation of PGRP-3 (1.3 fold) and PGRP-4 (1.6 fold) 
TLR2, TLR4 and NOD2 mRNA were also elevated in the placental samples. However, 
these changes were not statistically significant for this small sample size. 
 
 
Figure 12: PGRP expression- Fold changes between cases and controls  
 
Immunohistochemistry demonstrated positive staining for PGRPs 1, 3 and 4 in the 
syncytial trophoblasts. No positive staining was noted for PGRP 2. The IHC confirms our 
PCR results. We had to make sure we were using good positive controls, which included:  
- Acute appendicitis for PGRP 1 since neutrophils were known to express PGRP 1 
- Hepatocytes in the liver for PGRP 2 
- Keratinocytes for both PGRP 3 and PGRP 4 since they are known to be expressed in 
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skin by keratinocytes. The below slides are a cross-section through chorionic villi. The 
outer ring of cells, which are the syncytial trophoblasts appear to be staining. 
Immunohistochemistry Images:  
Figure 13: PGRP-1 Placenta        Acute Appendicitis ( +ve Control) 
                          
 
Figure 14: PGRP- 2 Placenta     Liver (+ve Control) 
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Figure 15: PGRP-3 Placenta                                       Keratinocytes    ( +ve Control) 
 
               
 
Figure 16: PGRP-4 Placenta        Keratinocytes (+ve Control) 
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Discussion: 
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Periodontal disease has been linked to various adverse pregnancy outcomes 
including pre-eclampsia, premature birth, low birth weight, intra uterine growth 
restriction, still birth etc. [31].  However, only two meta-analyses specifically 
investigating periodontal disease and preeclampsia have been performed which 
concluded that periodontal disease during pregnancy is associated with increased risk 
of pre-eclampsia (OR 1.76, CI- 1.43-2.18) [32] and periodontal disease appears to be a 
possible risk factor for pre-eclampsia (OR 2.17, CI- 1.38–3.41) [33]. However, there is 
a knowledge gap in understanding the underlying mechanisms, many of which could 
be attributed to the inherent limitations of the studies, including a high degree of 
variability in study populations, recruitment, assessment, disparities in data collection 
methods, inconsistent case definitions, which may under or over estimate the disease 
prevalence and not all the studies were investigating the same outcome variable. As a 
result, the studies included in the meta-analyses show a high degree of heterogeneity 
[34]. Also a majority of the studies in the literature are observational studies whose 
strength is modest and generalizability is an issue. There is a lack of studies 
investigating the biological mechanisms explaining the pathophysiology and risk 
profile of this association between periodontal disease and adverse pregnancy 
outcomes [31]. 
Four types of human PGRPs  (PGRP1, PGRP2, PGRP3 and PGRP4) have been 
recognized [13]. Constitutive PGRP expression has been demonstrated in various tissues 
including oral mucosal tissues and the tongue [13]. Mammalian PGRP1 is expressed in 
high levels in the bone marrow specifically in neutrophils and their precursors. In 
neutrophils, it is almost exclusively found in tertiary granules from where it can be 
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released by exocytosis. It is also expressed in low quantities in oral epithelial cells and 
fibroblasts and can be inducibly up-regulated in these cells in response to PGN [13]. 
PGRP2 is constitutively expressed in liver, which secretes it into blood. It is also 
expressed in lower levels in oral epithelial cells. Its expression is up-regulated in these 
cells and fibroblasts by bacteria and cytokines in NOD2 dependent manner [13]. PGRP3 
and PGRP4 are found in salivary glands specifically submandibular glands and in other 
oral tissues including tongue and throat.  Their expression is also up regulated by bacteria 
in keratinocytes, fibroblasts and other cells through TLR 2, TLR4, NOD1 and NOD2 
[13]. Initially, PGRPs were considered as anti-microbial PRR proteins [15]. However, 
recent evidence indicates that they can also modulate inflammation and immune 
responses independent of their bactericidal and enzymatic activities [16]. PGRPs are 
speculated to be involved in the pathogenesis of various inflammatory diseases like 
psoriasis, atherosclerosis, arthritis, ulcerative colitis, and Crohn’s disease [13]. 
Considering their role in various chronic inflammatory conditions, we hypothesized that 
PGRPs may play a significant role in the pathogenesis of pre-eclampsia. Inflammatory 
diseases appear to have common themes in their pathogenesis and are often found in 
combination with other co morbidities. Periodontitis is one such 
inflammatory disease, which appears to be associated with many systemic diseases such 
as diabetes, hypertension, obesity etc. There is evidence showing an association between 
periodontal disease and adverse pregnancy outcomes such as pre-eclampsia. We are 
interested in focusing on the role of innate immune mechanism in these inflammatory 
diseases. Pattern recognition receptors are a part of the innate immune mechanism, 
which have different classes of protein molecules of which PGRPs are one. Interestingly, 
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PGRPs are secreted proteins. Therefore they are quantifiable and measurable as a fluid 
biomarkers along with other clinical finding and in addition may exert effects on different 
organs. 
This is a pilot project specifically exploring the expression of PGRPs in relation to 
pre-eclampsia. Little is known about the role of PGRP in the immuno-modulation that is 
necessary to maintain homeostasis at the placental level. The studies that have been done 
so far are mainly epidemiological studies, which are mainly observational. More studies 
investigating the biological mechanisms involved in these inflammatory diseases are 
needed to understand the pathophysiological processes involved in order to design better 
therapeutic programs and identify individuals who are at risk and would actually benefit 
from them.  
 The sample size had to be reduced compared to the initially proposed number of 
20 samples in each group due to unforeseen issues related to the time in securing the 
samples, the cost involved as well as the limitations associated with the inclusion and 
exclusion criteria. Based on the preliminary data, our statistician stated that, in the initial 
proposal with 15 cases we would be able to detect an effect size of 1.1. The effect sizes 
with the data we had for PGRP1, PGRP4, and TLR4 were 0.27, 0.46, and 0.30, 
respectively. To have 80% power to detect an effect size of 0.50, we needed 64 samples 
per group, and to detect an effect size of 0.3 we needed 176 samples per group.  
We included women, who were non-smokers, BMI falling in the ‘normal’ range of 
(18.5-24.9) without any pathology associated with the pregnancy. We excluded smokers 
because of its inflammatory effects on both the periodontium and pregnancy and its 
associated profound confounding effect. There are reports of an association between 
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periodontal disease and inflammatory conditions such as diabetes and obesity, and they 
are known to negatively affect the pregnant women as well, hence the exclusion. We 
included births via Cesarean section only because the process of natural birth could 
trigger a separate inflammatory cascade, which would confound our results. 
Chorioamnionitis is an inflammation of the fetal membranes (amnion and chorion) due to 
a bacterial infection, which is also a confounding factor because potentially any 
expression of PGRPs could be in effect of the infection(s) and not pre-eclampsia. Since 
smoking and obesity rates are high in Indiana, it was not practical for us to procure ‘ideal’ 
samples, hence we decided to include overweight and slightly obese patients based on 
their BMI and obtain matching controls in order to control for bias to a certain extent.  
This is the first study on reporting the expression of PGRP1, PGRP3 and PGRP4 
in the human placenta; however, the mRNA levels were not significantly different 
between healthy samples and pre-eclamptic samples.  Our results were consistent with 
earlier reports of higher expression of TLR-2, TLR-4 an NOD-2 [24] in pre-eclampsia. 
The human placenta expresses transcripts for TLRs 1 through 10 and the proteins for 
many of these TLRs activate innate immune responses at the maternal–fetal interface 
[35].  TLR ligand-exposed trophoblasts secrete more proinflammatory cytokines and 
chemokines to enhance immune cell migration [35]. Among them, TLR-2 is known to 
recognize peptidoglycan from Gram-positive bacteria and TLR-4 is said to recognize 
lipopolysaccharide (LPS) from Gram-negative bacteria. TLR-4 expression was also 
reported increased in placental trophoblasts from women with pre-eclampsia. A study 
using pregnant rats has shown that low does of lipopolysaccharide acting via TLR-4 
induced pre-eclampsia like symptoms [36]. Many studies have stated an altered cytokine 
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profile in women with pre-eclampsia. To summarize, pre-eclamptic women showed 
increased TNF-α, IL-6 and IL-8 and decreased levels of IL-10 [35]. IL-10 is known to 
inhibit matrix metalloproteinases, which is critical for the trophoblast invasion during 
placentation. Also bacterial insult from distant sites could trigger release of pro-
inflammatory cytokines at the placental interface, which are directly cytotoxic to 
trophoblasts and prevent their migration into the uterine arties and lead to their apoptosis 
leading to hypoxia and consequently pre-eclamptic events. Since similar events and 
inflammatory factors are causal for periodontal events, biologically the association 
between the pre-eclampsia and periodontal disease seems plausible. Another interesting 
aspect to the inflammatory process in pre-eclampsia is that treatment if bacteriuria with 
sulfadimidine or sulfamethaxydiazine did not reduce the risk of pre-eclampsia. 
Additionally, Michalowicz et al. demonstrated that periodontal treatment during 
pregnancy did not significantly alter pre-eclampsia [36] may indicate that pre-eclampsia 
may not be a direct consequence of infection but due to the influence of pro-inflammatory 
cytokines secondary to infection which makes the investigation of PGRPs more valid. 
  This is the first study reporting on the expression of PGRP 1, 3 and 4 in human 
placental tissue. This was different from the result reported by Dziarski et al, where one 
placental sample was analyzed for PGRP expression, which did not show expression [30]. 
The clinical significance of this expression needs further investigation through 
longitudinal studies. Long-term data with a large sample size could help the obstetrics 
community better understand the pathogenesis of pre-eclampsia. It will also help bridge 
the gap in knowledge linking oral diseases to systemic conditions.  
Clinical Significance:  
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Considering that PGRPs are secreted proteins and therefore are quantifiable, the 
results of this study can lead to development of salivary and/or plasmatic biomarkers for 
early detection of pre-eclampsia. Understanding the role of PGRPs at the maternal-fetal 
interface may also provide potential new therapeutic targets for treating pre-eclampsia in 
the future and this is the first step in that direction.  
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Background: Pre-eclampsia a potentially life threatening hypertensive disorder 
occurring in 3-14% of pregnancies. Its etiology is multifactorial involving the 
placenta. The only “cure” that currently exists is the delivery of the baby, which 
is often pre-term. There is no early pregnancy screening test to recognize those 
at risk. Recently, an altered immune-inflammatory responses at the placental 
level in response to infectious agents (eg., periodontal pathogens) have been 
proposed to be etiological for this pregnancy complication. A new class of 
Pattern Recognition Receptors called Peptidoglycan Recognition Proteins 
(PGRPs) constituting 4 distinct molecules PGRP 1-4 is emerging as a key 
player in modulating host responses to peptidoglycan and its breakdown 
products. A critical knowledge gap exists on the role of PGRPs in the innate 
immune responses that occur at the maternal-fetal interface in response to 
pathogens and their components that may be present in maternal circulation 
secondary to chronic infections. Aim: The aim of this pilot study is to 
investigate the expression PGRPs in the placenta of pre-eclamptic women. The 
overall goal is to better understand the association of periodontal disease and 
adverse pregnancy outcomes.  
            Methods and Materials: This case control study consisted of subjects with: (1) 
normal term pregnancies (n=7) (2) pre-eclampsia (n=7). Preeclampsia was 
defined as hypertension (systolic blood pressure of ≥ 140 mm Hg or diastolic 
blood pressure of ≥ 90 mm Hg on at least 2 occasions, 4 hours to 1 week apart) 
and proteinuria (≥ 300 mg in a 24-hour urine collection or one dipstick 
measurement of ≥ 2+). A real time quantitative PCR array was used to analyze 
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the relative mRNA expression of TLR2, TLR4, NOD1, NOD2, PGRP1, 
PGRP2, PGRP3, and PGRP4. Immunohistochemistry was performed to 
determine the cell type(s) expressing the PGRP proteins in the placental tissue. 
Summary statistics (mean, standard deviation, range, 95% confidence interval 
for the mean) were calculated for PGRP 1-4 expression for each group.  
            Results and conclusions: The PCR data showed the expression of PGRPs 1, 3 
and 4 in the placental samples. There was an up-regulation of PGRP-1 (1.4 
fold) and down regulation of PGRP-3 (1.3 fold) and PGRP-4 (1.6 fold). TLR2, 
TLR4 and NOD2 mRNA were also elevated in the placental samples. 
Immunohistochemistry demonstrated positive staining for PGRPs 3 and 4 in the 
trophoblasts. The results from this novel research could lead to development of 
salivary and/or plasmatic biomarkers for early detection of PE and warrants 
further investigation 
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